Format

Send to

Choose Destination
Clin Nucl Med. 2017 Jun;42(6):e313-e316. doi: 10.1097/RLU.0000000000001620.

68Ga-DOTATATE PET/CT in Nonneuroendocrine Tumors: A Pictorial Essay.

Author information

1
From the Imaging Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Abstract

PET-CT with somatostatin analogs labeled with Ga is increasingly recognized as the best imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs). However, somatostatin receptor (SSR) is not an exclusive marker for NET. A variety of tumors other than NETs express SSR, leading to a significant risk of false-positive PET/CT results. We illustrate false-positive Ga-DOTATATE PET/CT findings due to high uptake by non-Hodgkin lymphoma, metastatic meningioma, breast cancer, thyroid adenoma, and papillary carcinoma. Although Ga-DOTATATE is a noteworthy tracer for oncological application, pathological conditions with overexpression of SSR should be recognized to prevent misinterpretation of PET/CT images.

PMID:
28240663
DOI:
10.1097/RLU.0000000000001620
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center